EGFR and metastatic colorectal cancer: Systemic anticancer therapy based on the chemotherapeutic agents 5-fluorouracil (5-FU)/capecitabine, oxaliplatin and irinotecan in combination with epidermal growth factor receptor (EGFR) or vascular endothelial growth factor inhibitors are the cornerstone of the treatment of metastatic colorectal cancer (mCRC)1.